Results 161 to 170 of about 1,586,161 (275)

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

open access: yesJournal of Diabetes, Volume 18, Issue 10, October 2026.
This large‐scale real‐world Chinese study demonstrates glycemic clinical control rates (HbA1c > 7%) at baseline and 6 months across key subgroups, including age, baseline HbA1c, body mass index, and treatment regimen. In this prospective real‐world study of fixed‐dose combination metformin and empagliflozin in Chinese patients with type 2 diabetes ...
Weijian Ke   +51 more
wiley   +1 more source

Human β‐Cell Dedifferentiation and Diabetes

open access: yesJournal of Diabetes, Volume 18, Issue 10, October 2026.
Human β‐cell dedifferentiation is inversely associated with HOMA‐β and occurs in Type 2 diabetes, Type 3c diabetes, and age‐related diabetes, potentially before hyperglycemia develops. Progressive loss of β‐cell identity is accompanied by dedifferentiation and transdifferentiation, suggesting that reversing these cell‐state changes may help restore ...
Jiajun Sun, Jinsook Son, Qidi Wang
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli   +3 more
wiley   +1 more source

Under‐ and overdosing insulin in the hospital: A retrospective cohort study of dose deviation and patient outcomes

open access: yesDiabetic Medicine, Volume 43, Issue 10, October 2026.
Abstract Aims Glycaemic abnormalities during hospitalization are common and linked to morbidity and mortality, yet little is known about how deviations from guideline‐recommended insulin dosing affect outcomes. The aim of this study is to examine whether deviation from an expected insulin dose in non‐critically ill hospitalized adults with type 2 ...
Hussein Zaitoon   +5 more
wiley   +1 more source

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9607-9620, October 2026.
ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Linong Ji   +6 more
wiley   +1 more source

Comparative effectiveness of pioglitazone and sitagliptin added to metformin and sulfonylurea in patients with type 2 diabetes: An emulated target trial. [PDF]

open access: yesMedicine (Baltimore)
Kim TH   +14 more
europepmc   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9101-9111, October 2026.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda   +4 more
wiley   +1 more source

Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials. [PDF]

open access: yesNephrol Dial Transplant
van Baar MJB   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy